ACTO Named Luminary in Everest Group 2026 Agentic AI Life Sciences Report
ACTO earns Luminary status in the 2026 Everest Group report for its innovative, regulated agentic AI solutions designed specifically for life sciences…
ACTO earns Luminary status in the 2026 Everest Group report for its innovative, regulated agentic AI solutions designed specifically for life sciences…
Avantor, Inc. confirms it will report its Q3 2026 financial results before the market opens, marking a routine update for the life…
Scribe Therapeutics, backed by Eli Lilly, raised $128.7 million in an upsized IPO, reflecting strong investor demand for biotech firms with major…
Aragen Life, backed by Quadria Capital, plans a $300 million India IPO, signaling robust capital markets activity and investor appetite for life…